MedPath

The efficacy of combination of Olanzapine, Aprepitant, Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving autologous peripheral blood stem cell transplantation for multiple myeloma

Phase 2
Conditions
multiple myeloma
Registration Number
JPRN-UMIN000035970
Lead Sponsor
Hitachi general hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
52
Inclusion Criteria

Not provided

Exclusion Criteria

1)Uncontrolled active infection. 2)Active gastrointestinal ulcer. 3)Serious psychiatric illness. 4)Patient who is judged to be medically unfit by physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete response rate for the delayed phase (24-120 hours), defined as no emetic episodes and no use of rescue medication
Secondary Outcome Measures
NameTimeMethod
Complete response rate for the acute phase (0-24 hours) and the overall phase (0-120 hours). Complete control rate for the acute, delayed and overall phase.
© Copyright 2025. All Rights Reserved by MedPath